logo-loader

XPhyto Therapeutics taps Knox Communications to carry out marketing and investor relations

Published: 08:25 01 Jul 2020 EDT

XPhyto Therapeutics Corp. - XPhyto Therapeutics Corp taps Knox Communications Inc to carry out marketing and investor communication activities for the company
XPhyto said the agreement became effective July 1 for 12 months and that it has granted Henderson stock options to purchase 100,000 common shares at $2.50 apiece for a period of one year

XPhyto Therapeutics Corp (CSE:XPHY) (FSE:4XT) (OTCPINK:XPHYF) said Wednesday it has entered into an investor-relations consulting agreement with Knox Communications Inc (KCI) to carry out marketing and investor communication activities for the company.

KCI's founder and principal, Knox Henderson, brings more than 25 years' experience in investor relations, corporate finance and communications for publicly listed companies, XPhoto noted in a statement.

READ: XPhyto Therapeutics partners with German biotech firm to develop coronavirus screening test

Henderson has advised a broad range of early and growth-stage companies in the life sciences, technology and resource sectors, it added. His most recent major engagement involves notable success in the Canadian junior capital markets.

The company noted that Henderson was formerly a CSC-designated trader on the Canadian equities markets.

XPhyto said the agreement became effective July 1 for a term of 12 months and that it has granted Henderson stock options to purchase 100,000 common shares at $2.50 apiece for a period of one year. The options will vest in four equal tranches over the term of the agreement beginning three months from issuance.

Vancouver-based XPhyto is a biopharma, diagnostics and cannabis science company focused on formulation, clinical validation, and European imports, distribution and sales.

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 53 minutes ago